Biosimilars vs Biologic Originators: Similar Safety, Efficacy for Psoriasis, Hidradenitis Suppurativa?
Apr 8, 2021 Good results from two studies, but questions remain Researchers of two recent studies — from Denmark and the U.S. — sought to determine whether biosimilars are as effective as their biologic originators in the treatment of psoriasis and of hidradenitis suppurativa. JAMA Dermatology, researchers from Denmark concluded that the biosimilar for adalimumab may be as effective as adalimumab originator for the treatment of patients with psoriasis. Patients who switched to an adalimumab...
Source: physiciansweekly.com